Exercise prevents neuronal damage caused by lung cancer treatment

by Hospital Universitari de Bellvitge

A study of IDIBELL, ICO, and Bellvitge University Hospital shows that exercise not only prevents the loss of neuronal tissue caused by chemotherapy and radiotherapy. Also, patients who follow sports g...

Read more

Seeking out predictive biomarkers for a longer-term response to immunotherapy against NSCLC

by VHIO

While the rapidly emerging arsenal of immune-based therapies continues to show great promise in more effectively tackling an increasing number of tumor types including melanoma and lung cancer, these ...

Read more

ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...

Read more

ORYZON presents efficacy and safety results of its CLEPSIDRA trial with iadademstat in ED-SCLC patients at ESMO-2020

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today...

Read more

Lung Cancer: The addition of chemotherapy to EGFR inhibitor therapy improved survival in advanced EGFR-mutant NSCLC in two independent studies, compared with targeted therapy alone

by OncoDNA

The addition of chemotherapy to EGFR inhibitor therapy improved survival in advanced EGFR-mutant NSCLC in two independent studies, compared with targeted therapy alone

Read more

LUNG CANCER: Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 tria

by OncoDNA

Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 trial. For patients with pre-treated NSCLC with EGFR exon 20 insertion mut...

Read more

ORYZON presents positive efficacy results on iadademstat in ED-SCLC patients at ESMO-2019

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announc...

Read more

Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer

by Pivotal

​Pivotal, a specialist CRO, has been awarded two clinical trials for a novel investigational immunotherapy drug and patient enrolment has now started. Pivotal will use its deep knowledge of Oncology...

Read more

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting

by Ability Pharma

​AbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2...

Read more

ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)

by Oryzon Genomics

Complete and durable tumor regression occurred with Iadademstat–induced NOTCH activation in a chemoresistant PDX model. Further supports LSD1 inhibitors as a possible new and targeted therapy for SC...

Read more

An international clinical trial extends the effectiveness of immunotherapy to more lung cancer patients

by CNIO - Centro Nacional de Investigaciones Oncológicas

Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma "significantly increases" the survival of patients, write the authors in The New England Journal of Medici...

Read more

Oryzon receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)

by Oryzon Genomics

The study, named CLEPSIDRA, will be conducted in several Spanish hospitals . CLEPSIDRA is a single - arm, open - label study of Iadademstat in combination with the standard of care treatment p latinum...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

by Labo'Life

Photos Stream